First patient dosed in phase 3 XTEND-Kids study with efanesoctocog alfa in children with haemophilia A
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announced that the first patient has been dosed in the phase 3, open-label, interventional XTEND-Kids study of efanesoctocog alfa (BIVV001) in paediatric subjects with severe haemophilia A. The XTEND-Kids study is designed to investigate the efficacy, safety and pharmacokinetics of efanesoctocog alfa as once-weekly prophylaxis in approximtately 65 previously treated patients ≤12 years of age. Duration of treatment in the study is 52 weeks. Efanesoctocog alfa is being developed and will be commericalized in partnership